Spots Global Cancer Trial Database for cik
Every month we try and update this database with for cik cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Treatment of Metastatic Tumors of the Urogenital Area With Cytokine-induced Killer Cells | NCT05108077 | Bladder Cancer Renal Cancer | cytokine-induce... Standard treatm... | 18 Years - 80 Years | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | |
| Evaluation of Cytokine-induced Killer (CIK) Cells as Therapy or Adjuvant Treatment for Advanced HCC | NCT02568748 | Liver Cancer | CIK TACE | - | Tanta University | |
| Safety and Efficacy of γδ T Cell Against Gastric Cancer | NCT02585908 | Gastric Cancer | CIK γδ T CIK and γδ T | 30 Years - 75 Years | Beijing Doing Biomedical Co., Ltd. | |
| Effect of Cytokine-induced Killer Cells for Stage I-II Malignant Gliomas | NCT02494804 | Cytokine-Induce... Milignant Gliom... | Temozolomide CIK | 18 Years - 80 Years | The First People's Hospital of Changzhou | |
| The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR | NCT02493582 | Adenocarcinoma ... | Cytokine-Induce... Apatinib | 18 Years - 70 Years | The First People's Hospital of Changzhou | |
| CIK Cell Transfusion Plus Gefitinib As Second Or Third-Line Treatment for Advanced Adenocarcinoma Non-Small Cell Lung Cancer | NCT01871480 | Non-Small Cell ... | Group A:cytokin... Group B:Gefitin... | 18 Years - 80 Years | Kunming Medical University | |
| Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas | NCT02496988 | Cytokine-Induce... Advanced Milign... | Temozolomide CIK | 18 Years - 80 Years | The First People's Hospital of Changzhou | |
| Safety and Efficacy of γδ T Cell Against Gastric Cancer | NCT02585908 | Gastric Cancer | CIK γδ T CIK and γδ T | 30 Years - 75 Years | Beijing Doing Biomedical Co., Ltd. | |
| Effect of Cytokine-induced Killer Cells for Stage I-II Malignant Gliomas | NCT02494804 | Cytokine-Induce... Milignant Gliom... | Temozolomide CIK | 18 Years - 80 Years | The First People's Hospital of Changzhou | |
| The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer | NCT02485015 | Stomach Neoplas... | Cytokine-Induce... Apatinib | 18 Years - 70 Years | The First People's Hospital of Changzhou | |
| The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous Cytokine-induced Killer Cells | NCT01868490 | Cholangiocarcin... | cytokine induce... | 8 Years - 60 Years | Siriraj Hospital | |
| Autologous Cytokine-induced Killer Cells Combined Chemotherapy in Advanced Pancreatic Cancer | NCT03002831 | Advanced Cancer | Cytokine-induce... Tegafur-Gimerac... | 18 Years - | Henan Cancer Hospital | |
| CIK Cell Transfusion Plus Gefitinib As Second Or Third-Line Treatment for Advanced Adenocarcinoma Non-Small Cell Lung Cancer | NCT01871480 | Non-Small Cell ... | Group A:cytokin... Group B:Gefitin... | 18 Years - 80 Years | Kunming Medical University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
